Supplementary Figures 1-7: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Supplementary Figure 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Summary of results from assessment of studies using the Cochrane risk of bias tool.

Supplementary Figure 2. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Forest plots depicting results of head-to-head comparisons in according to Bayesian pairwise and network meta-analyses. Results of all comparisons in overall survival (A) and progression free survival (B).

Supplementary Figure 3. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Pooled estimates of the network meta-analysis. Pooled hazard ratios (95% credible intervals) for overall survival (upper triangle) and progression free survival (lower triangle) for patients untreated (A) and for patients with advanced lung cancer receiving checkpoint inhibitors monotherapy (B) and combination therapy (C). Ranking curves are described according to the Bayesian ranking results presented in supplementary table S3.

<1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.ICI= immune checkpoint inhibitor; niv= nivolumab; ipi= ipilimumab; PlaCT= platinum-based chemotherapy.

Supplementary Figure 4. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Forest plots depicting results of head-to-head comparisons in according to Bayesian pairwise and network meta-analyses. Forest plot with chemotherapy as reference in patients with previously untreated advanced lung cancer subgroup (A, B), in patients with advanced lung cancer receiving checkpoint inhibitors monotherapy (C, D) and combination therapy (E, F) subgroup.

<1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.

Supplementary Figure 5. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Forest plot in patients with advanced lung cancer receiving PD-1 inhibitors subgroup (A, B) and receiving PD-L1 inhibitors (C, D) subgroup. (E-H) Corresponding Bayesian ranking profiles of comparable treatments. Ranking curves are described according to the Bayesian ranking results presented in supplementary table S3.

<1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%. immunotherapy= immune checkpoint inhibitor; Prior_chem=previously treated with platinum-based chemotherapy.

Supplementary Figure 6. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Pooled estimates of the network meta-analysis. Pooled hazard ratios (95% credible intervals) for overall survival (upper triangle) and progression free survival (lower triangle) for patients with <1% PD-L1 expression (A), with 1-49% PD-L1 expression (B) and with ≥50% PD-L1 expression(C). Ranking curves are described according to the Bayesian ranking results presented in supplementary table S5.

<1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.ICI= immune checkpoint inhibitor; Pem= pembrolizumab; ate= atezolizumab; niv= nivolumab; ipi= ipilimumab; sin= sintilimab, tis=tislelizumab; cem= cemiplimab; DoCT= docetaxel chemotherapy; PlaCT= platinum-based chemotherapy.

Supplementary Figure 7. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Bayesian ranking profiles of comparable treatments on OS and PFS for patients with PD-L1<1% (A, B), 1-49% (C, D), ≥50% (E, F). Ranking curves are described according to the bayesian ranking results presented in supplementary table S4. PlaCT= platinum-based chemotherapy.